Trans -Splicing,More Than Meets the Eye: Multifaceted Therapeutics for Spinal Muscular Atrophy

Abstract

Get full access to this article

View all access options for this article.

References

Avila

A.M.

, Burnett

B.G.

, Taye

A.A.

et al. 2007. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J. Clin. Invest., 117:659–671.

Azzouz

, Le

, Ralph

G.S.

et al. 2004. Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J. Clin. Invest., 114:1726–1731.

Baughan

, Shababi

, Coady

T.H.

et al. 2006. Stimulating full-length SMN2 expression by delivering bifunctional RNAs via a viral vector. Mol. Ther., 14:54–62.

Baughan

T.D.

, Dickson

, Osman

E.Y.

et al. 2009. Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy. Hum. Mol. Genet., 18:1600–1611.

Burghes

A.H.M.

, Beattie

C.E.

2009. Spinal muscular atrophy: Why do low levels of survival motor neuron protein make motor neurons sick? Nat. Rev. Neurosci., 10:597–609.

Butchbach

M.E.R.

, Burghes

A.H.M.

2004. Perspectives on models of spinal muscular atrophy for drug discovery. Drug Disc. Today Dis. Models, 1:151–156.

Butchbach

M.E.R.

, Singh

, Thorsteindóttir

et al. 2010. Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Hum. Mol. Genet., 19:454–467.

Coady

T.H.

, Lorson

C.L.

2010. Trans-splicing-mediated improvement in a severe mouse model of spinal muscular atrophy. J. Neurosci., 30:126–130.

Coady

T.H.

, Shababi

, Tullis

G.E.

et al. 2007. Restoration of SMN function: Delivery of a trans-splicing RNA re-directs SMN2 pre-mRNA splicing. Mol. Ther., 15:1471–1478.

10.

Coady

T.H.

, Baughan

T.D.

, Shababi

et al. 2008. Development of single vector system that enhances trans-splicing of SMN2 transcripts. PLoS One, 3:e3468.

11.

Coovert

D.D.

, Le

T.T.

, McAndrew

P.E.

et al. 1997. The survival motor neuron protein in spinal muscular atrophy. Hum. Mol. Genet., 6:1205–1214.

12.

Crawford

T.O.

, Pardo

C.A.

1996. The neurobiology of childhood spinal muscular atrophy. Neurobiol. Dis., 3:97–110.

13.

De Vry

, Martínez-Martínez

, Losen

et al. 2010. In vivo electroporation of the central nervous system: A non-viral approach for targeted gene delivery. Prog. Neurobiol., 92:227–244.

14.

Dickson

, Osman

, Lorson

C.L.

2008. A negatively acting bifunctional RNA increases survival motor neuron both in vitro and in vivo. Hum. Gene Ther., 19:1307–1315.

15.

Dominguez

, Marais

, Chatauret

et al. 2011. Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice. Hum. Mol. Genet., 20:681–693.

16.

Foust

K.D.

, Wang

, McGovern

V.L.

et al. 2010. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. Nat. Biotechnol., 28:271–274.

17.

Gavrilina

T.O.

, McGovern

V.L.

, Workman

et al. 2008. Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle specific SMN expression has no phenotypic effect. Hum. Mol. Genet., 17:1063–1075.

18.

Hastings

M.L.

, Berniac

, Liu

Y.H.

et al. 2009. Tetracyclines that promote SMN2 exon 7 splicing as therapeutics for spinal muscular atrophy. Sci. Transl. Med., 1:5–12.

19.

Herweijer

, Wolff

J.A.

2007. Gene therapy progress and prospects: Hydrodynamic gene delivery. Gene Ther., 14:99–107.

20.

Hsieh-Li

H.M.

, Chang

J.G.

, Jong

Y.J.

et al. 2000. A mouse model for spinal muscular atrophy. Nat. Genet., 24:66–70.

21.

Hua

, Vickers

T.A.

, Okunola

H.L.

et al. 2008. Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am. J. Hum. Genet., 82:834–848.

22.

Hua

, Sahashi

, Hung

et al. 2010. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev., 24:1634–1644.

23.

Jarecki

, Chen

, Bernardino

et al. 2005. Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: Early leads towards a therapeutic for spinal muscular atrophy. Hum. Mol. Genet., 14:2003–2018.

24.

Kaspar

B.K.

, Lladó

, Sherkat

et al. 2003. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science, 301:839–842.

25.

T.T.

, Pham

L.T.

, Butchbach

M.E.R.

et al. 2005. SMND7, the major product of the centromeric survival motor neuron gene (SMN2), extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum. Mol. Genet., 14:845–857.

26.

Lefebvre

, Bürglen

, Reboullet

et al. 1995. Identification and characterization of a spinal muscular atrophy-determining gene. Cell, 80:155–165.

27.

Lefebvre

, Burlet

, Liu

et al. 1997. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat. Genet., 16:265–269.

28.

Lepore

A.C.

, Haenggeli

, Gasmi

et al. 2007. Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1^G93A model of ALS. Brain Res., 1185:256–265.

29.

Lorson

C.L.

, Hahnen

, Androphy

E.J.

et al. 1999. A single nucleotide in the SMN gene regulates splicing an is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. U.S.A., 96:6307–6311.

30.

Marquis

, Meyer

, Angehrn

et al. 2007. Spinal muscular atrophy: SMN2 pre-mRNA splicing corrected by a U7 snRNA derivative carrying a splicing enhancer sequence. Mol. Ther., 15:1479–1486.

31.

McAndrew

P.E.

, Parsons

D.W.

, Simard

L.R.

et al. 1997. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMN^T and SMN^C gene copy number. Am. J. Hum. Genet., 60:1411–1422.

32.

Meyer

, Marquis

, Trüb

et al. 2009. Rescue of a severe mouse model for spinal muscular atrophy by U7 snRNA-mediated splicing modulation. Hum. Mol. Genet., 18:546–555.

33.

Michaud

, Arnoux

, Bielli

et al. 2010. Neuromuscular defects and breathing disorders in a new mouse model of spinal muscular atrophy. Neurobiol. Dis., 38:125–135.

34.

Monani

U.R.

, Lorson

C.L.

, Parsons

D.W.

et al. 1999. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol. Genet., 8:1177–1183.

35.

Monani

U.R.

, Sendtner

, Coovert

D.D.

et al. 2000. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn^–/– mice and results in a mouse with spinal muscular atrophy. Hum. Mol. Genet., 9:333–339.

36.

Monani

U.R.

, Pastore

M.T.

, Gavrilina

T.O.

et al. 2003. A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy. J. Cell Biol., 160:41–52.

37.

Narver

H.L.

, Kong

, Burnett

B.G.

et al. 2008. Sustained improvement of spinal muscular atrophy mice treated with trichostatin A plus nutrition. Ann. Neurol., 64:465–470.

38.

Passini

M.A.

, Bu

, Roskelley

E.M.

et al. 2010. CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy. J. Clin. Invest., 120:1253–1264.

39.

Pathak

, Patnaik

, Gupta

K.C.

2009. Recent trends in non-viral vector-mediated gene delivery. Biotechnol. J., 4:1559–1572.

40.

Riessland

, Ackermann

, Förster

et al. 2010. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Hum. Mol. Genet., 19:1492–1506.

41.

Schrank

, Götz

, Gunnersen

J.M.

et al. 1997. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc. Natl. Acad. Sci. U.S.A., 94:9920–9925.

42.

Shababi

, Glascock

, Lorson

C.L.

2011. Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy. Hum. Gene Ther., 22:135–144.

43.

Singh

N.K.

, Singh

N.N.

, Androphy

E.J.

et al. 2006. Splicing of a critical exon of human survival motor neuron is regulated by a unique silencer element located in the last intron. Mol. Cell. Biol., 26:1333–1346.

44.

Skordis

, Dunckley

M.G.

, Yue

et al. 2003. Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc. Natl. Acad. Sci. U.S.A., 100:4114–4119.

45.

Thurmond

, Butchbach

M.E.R.

, Palomo

et al. 2008. Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy. J. Med. Chem., 51:449–469.

46.

Valori

C.F.

, Ning

, Wyles

et al. 2010. Systemic delivery of scAAV9 expressin SMN prolongs survival in a model of spinal muscular atrophy. Sci. Transl. Med., 2:35–42.

47.

Viola

J.R.

, El-Andaloussi

, Oprea

I.I.

et al. 2010. Non-viral nanovectors for gene delivery: Factors that govern successful therapeutics. Expert Opin. Drug Deliv., 7:721–735.

48.

Williams

J.H.

, Schray

R.C.

, Patterson

C.A.

et al. 2009. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy. J. Neurosci., 29:7633–7638.

49.

Wood

, Yin

, McClorey

2007. Modulating the expression of disease genes with RNA-based therapy. PLoS Genet., 3:e109.

50.

Workman

, Saieva

, Carrel

T.L.

et al. 2009. A SMN missense mutation complements SMN2 restoring snRNPs and rescuing SMA mice. Hum. Mol. Genet., 18:2215–2229.